Edmonton Health Matters: Experimental therapy helps man see
An Alberta man with severe vision loss can now see things he hasn’t been able to since he was a child. As Su-Ling Goh reports, the RNA therapy that helped patient Dean Scott is being called a “game-changer” for various types of blindness.
Natural Killer Cells Plus Immunotherapy for Triple-Negative Breast Cancer
Q: Your experimental protocol was given as third-line treatment, is that correct? Most patients were on their third line of treatment, but inclusion criteria were beyond first-line standard of care.
Ingestible Diagnostics: Technical Challenges, Regulatory Considerations, and Reimbursement
A number of ingestible technologies have been developed for the diagnosis of gastrointestinal (GI) diseases, including the use of conventional tools, such as endoscopy, radiological imaging, or biochemical tests. Ingestible diagnostics are particularly useful for the exploration of the small bowelii, since gastroscopy can only reach a limited area of the small intestine and alternative methods with further reach, such as balloon enteroscopy, require specific expertise and infrastructure.
After digging through discards, biotech startup is making a $45M bet it can fix a failed cancer therapy
“Their Phase I data was stellar, great Phase I, and then they had this Phase II that failed primarily because they added the wrong drug,” Asher Nathan, CEO and co-founder of NeoTX, told Endpoints News as he unveils $45 million in new financing.
The Process Behind The Potential: Cue Biopharma’s Therapy For HPV16-Related Malignancies
A look into Cue Biopharma’s engineering-centric approach to in vivo tumor antigen specific T cell activation. Late last month, Cue Biopharma shared preclinical and translational data supporting the therapeutic potential of CUE-101 in HPV16-related malignancies.
Tackling unmet needs: new compounds in development for non-functioning pituitary adenomas and rare endocrine diseases
In today’s podcast, we highlight a new company dedicated to the rare endocrine disease world. Tiburio Therapeutics is working on two exciting compounds for the treatment of Non-functioning Pituitary Adenomas and rare endocrine disorders.
Developing Novel Therapies for Central Nervous System Diseases with Brad Margus Cerevance
Brad Margus, CEO, Cerevance talks about discovering and developing novel therapies for central nervous system diseases using the Cerevance powerful NETSseq target discovery platform and their large collection of human brain tissue samples. Brad explains why the brain is such a challenging organ to study and their efforts to understand brain cell loss in such diseases as Parkinson’s and Alzheimer’s.
Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo
For the last year, biopharma veteran Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate, sacituzumab govitecan. Now, she’s signing on with the company full-time as its new chief medical officer.
